Sanofi faces Pompe disease treatment supply disruption due to manufacturing facility issues
SNY Sanofi ADR
$46.06 -2.25%
View chart & analysis → - 1Sanofi stated that administration for some US patients could be suspended until late November due to delivery delays.
- 2The FDA inspected the Ireland manufacturing facility between January 12 and January 20, 2026.
- 3Approximately 1 in 19,000 babies is born with Pompe disease.
So what's the key point?
Problems at the factory where Sanofi makes its medicine may prevent timely delivery to patients in the US. This could cause treatment to stop for some patients until late November.
Source CNBC · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.